Clinical trials showed 99.9% of participants who received the drug, called Yeztugo​ from company Gilead Sciences, remained ...

FRIDAY, June 20, 2025 (HealthDay News) — A new shot to prevent HIV infection has just been approved — and it only needs to be ...

Although largely as expected by investors, BMO Capital says lenacapavir’s approval for prevention, now known as Yeztugo, marks “a major win for Gilead (GILD)” in driving meaningful growth in its ...

The approval of lenacapavir for use as pre-exposure prophylaxis is a significant step in reducing the incidence of HIV across ...

The FDA approval marks the first approval of a type of pre-exposure prophylaxis that would only require 2 treatments per year ...

The FDA approved Gilead's HIV prevention drug lenacapavir, a twice-a-year injectable medication that clinical trials show ...

Managed Healthcare Executive gives C-suite executives in health plans and provider organizations news and strategies for ...

WHO celebrates FDA's nod to injectable lenacapavir for HIV prevention, promising easier adherence with biannual doses.

The US Food and Drug Administration approves Wednesday, June 18, Gilead Sciences lenacapavir, a twice-yearly injection, for ...

With FDA Approval, MISTR Is Set to Deliver Nationwide Access to Lenacapavir Ushering in a New Era of HIV Prevention Two Shots ...

The breakthrough double injection won’t be cheap in the US, although scientists argue it could (and should) be.

The US FDA has approved lenacapvir, sold under the brand name Yeztugo, as the first preventive treatment against HIV. It is a ...